article thumbnail

Wegovy backorder: Why it happens and what to do about it

The Checkup by Singlecare

Wegovy (semaglutide) is an injectable medication approved in 2021 for people with obesity or who are overweight and have a weight-related medical condition. Others have just waited or turned to a compounded version of the drug,” Dr. Jordan says. It’s injected weekly to help lose weight and maintain weight loss.

article thumbnail

Reducing Drug Spend with IV Robotic Services

Omnicell

Sterile compounding is also one of the costliest functions in pharmacy operations. Still, many hospital pharmacies continue to struggle to improve safety and efficiency in their sterile compounding operations. Insourcing IV compounding services at Moses H. Register today at Omnicell Illuminate 2021. 5 at 2 p.m.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

CD19 CAR-T agents to boost blood cancer market

European Pharmaceutical Review

Research from data and analytics company GlobalData shows that the use of CD19 chimeric antigen receptor T-cell (CAR-T) agents for blood cancer is set to significantly increase between 2021-2031. Breyanzi will exhibit the largest compound annual growth rate (CAGR) at 30 percent, compared to Yescarta’s CAGR of 9 percent.

article thumbnail

Does Medicare cover Ozempic?

The Checkup by Singlecare

Unfortunately, a law from 2003 prohibits Medicare Part D from covering weight loss drugs, which means it won’t cover Ozempic prescribed solely for weight loss , an off-label use. Factors influencing Medicare coverage of Ozempic for diabetes In 2021, Medicare spent more than $2.6

article thumbnail

How long does it take for trazodone to work?

The Checkup by Singlecare

Results from a 2021 review of clinical trials showed that people with major depressive disorder (MDD) reported significant improvement in as little as one week. Anxiety Unlike depression, anxiety is an off-label use for trazodone. The same 2021 review found that patient improvements weren’t significant after seven days but after 21.

article thumbnail

Entrance of novel therapies will drive Niemann-Pick type C disease market growth

Pharmaceutical Technology

According to GlobalData’s recent Niemann-Pick Type C (NPC): Opportunity Analysis and Forecast to 2031 report, the NPC market is expected to see significant growth during 2021–31. This sales growth will be in line with a steadily increasing disease prevalence and the entrance of novel agents into the market.

article thumbnail

Atomoxetine interactions to avoid

The Checkup by Singlecare

Since atomoxetine treats attention-deficit hyperactivity disorder by being a selective norepinephrine reuptake inhibitor and since norepinephrine is an adrenaline compound, MAOIs are hazardous if taken concurrently or within 14 days of atomoxetine. MAOIs can lead to an increase in adrenaline.